South Korean startups use TechCrunch’s Seoul stage to chase U.S. growth, with Voinosis taking top honors

Voinosis won the top spot at DETO 2026 in Seoul after nine South Korean startups pitched for a chance to reach TechCrunch Disrupt 2027’s Startup Battlefield 200. The contest mattered because all nine companies are aiming at the U.S. market, making the event a focused test of which Korean deep-tech startups can turn domestic momentum into international traction.

What happened in Seoul?

TechCrunch reported that nine early-stage South Korean startups presented at DETO 2026 this week, competing for selection into Startup Battlefield 200, TechCrunch’s annual global startup competition tied to Disrupt. The winner was Voinosis, an AI brain-health voice analysis company that stood out in a field spanning healthcare, fintech, energy, semiconductors and AI.

That mix says as much about the event as the result. This was not a single-sector showcase built around consumer apps or software tooling. It was a cross-section of the kind of hardware-heavy, infrastructure-minded startups that often need large markets, specialized partners and patient capital to scale. For many of the companies, the U.S. is the next obvious step.

Why it matters

The Seoul pitch event matters because it puts a spotlight on how South Korean startups are increasingly using U.S.-linked stages as launchpads for expansion. Startup Battlefield 200 offers not just visibility, but a route into one of the best-known startup conferences in the world. For founders building in deep tech, that can mean access to investors, customers and strategic partners beyond Korea’s domestic market.

It also shows how early-stage Korean companies are framing their businesses for global markets from the start. Instead of treating U.S. entry as a distant possibility, the startups at DETO 2026 are already pitching products with international deployment in mind — from hospital diagnostics and warehouse robotics to memory hardware and identity infrastructure.

That matters for readers because competition for scaling capital is fierce, and because the companies that can make cross-border expansion work often define the next wave of industrial and AI adoption. If even a handful of these firms break through in the U.S., the ripple effects could reach healthcare, mobility, security and semiconductors.

Why did Voinosis stand out?

Voinosis won with a health-tech pitch built around voice analysis as a way to detect possible brain-health changes. According to TechCrunch, the startup examines pitch, pauses, rhythm and response times, then uses those signals to flag changes that may warrant attention.

The company says the process takes less than five minutes and can be tested across languages without separate language training. It also says a clinical study involving 146 participants found 88% accuracy in screening for potential cognitive issues. Those claims help explain why the company attracted attention in a competition full of technically ambitious startups.

Voinosis is targeting hospitals, senior living facilities, insurers and consumers, giving it multiple possible paths to revenue if the product proves reliable at scale. The startup was founded by Grace Shin, a former otologic surgeon with more than 25 years of experience. TechCrunch also reported that the company is raising a Series A and already has a strategic investor from South Korea’s pharmaceutical sector.

“less than 5 minutes”

Inside the field: who else pitched?

TechCrunch’s report describes a lineup of companies that reflects the breadth of South Korea’s deep-tech pipeline. Some are building in healthcare, others in robotics, energy, security or chip design. Several are tackling industrial problems that are difficult to solve with software alone.

Here is a snapshot of the nine startups and the problems they are aiming at:

How is this a signal for South Korean deep tech?

It is a signal that South Korean deep tech is looking outward at the same time it is maturing at home. The startups in Seoul were not pitching as local niche plays. They were framing products that could sell into hospitals, factories, warehouses, defense-adjacent applications, mobility platforms and global enterprise workflows.

That matters because deep-tech companies usually need longer development cycles and more capital than typical software startups. Their path to growth often depends on proving technical performance, finding design partners, and showing that the product can cross regulatory and operational hurdles in more than one market. A U.S. expansion plan is therefore not just marketing; it is part of the business model.

The event also shows that TechCrunch’s competition format remains influential far beyond Silicon Valley. Startup Battlefield 200 is annual, global and connected to Disrupt, which means that a Seoul pitch event can serve as a feeder into a much larger international conversation.

Background: how we got here

TechCrunch describes Startup Battlefield 200 as its annual global startup competition tied to Disrupt. Over the years, that format has become a shorthand for early-stage companies hoping to gain legitimacy, attention and a shot at broad visibility. For founders with capital-intensive technologies, appearing on that kind of stage can matter almost as much as a financing round.

South Korean startups have increasingly looked to the U.S. as a place to scale. That is especially true for companies with products that are technically complex or built for regulated industries. The domestic market may be important, but it can also be too small to support the kind of growth investors expect from companies in healthcare hardware, chips or robotics.

DETO 2026 in Seoul fits that pattern. The event brought together companies from different sectors, but they shared a common ambition: move beyond Korea and compete in the U.S. TechCrunch’s report suggests that ambition is not abstract. It is central to how these founders are positioning their businesses right now.

The broader startup context

Deep tech tends to reward technical proof over flashy branding. That is why the details in TechCrunch’s report matter. Voinosis points to clinical testing, Otition Medical to image training data and certification, Ternell to measured chip performance, and Riibotics to deployment speed. In each case, the pitch is grounded in an operational claim that can be tested by customers or investors.

That style of pitching fits the current market. Buyers want measurable performance, and investors want evidence that the technology can survive contact with the real world. For startups aiming at U.S. expansion, those standards are even higher.

What the numbers say

The clearest way to see the scope of the event is through the figures TechCrunch reported. The table below pulls together the key numbers attached to the pitches and the broader competition.

Who is Voinosis, and what does it claim to do?

Voinosis is an AI startup focused on brain-health analysis through voice. Its software examines speech patterns — including pitch, pauses, rhythm and response times — to identify possible changes in brain health. The company says its approach can be used in less than five minutes and without separate training for different languages.

The startup is led by Grace Shin, who TechCrunch says spent more than 25 years as an otologic surgeon. That background is important because it places the company at the intersection of clinical experience and machine-learning application. The startup is now raising a Series A and already has a strategic investor from South Korea’s pharmaceutical industry.

For a company like Voinosis, the likely challenge is not only building accurate software but proving that it can fit into the routines of hospitals, senior living facilities and insurers. That is where the next phase of its story begins.

“88% accuracy”

What other startup categories were represented?

The range of companies in Seoul shows how broad South Korea’s startup ambitions are. The pitches covered several different layers of the modern tech stack:

• Healthcare: Voinosis and Otition Medical
• Energy: Awesome Lab
• Security and payments: Crosshub
• Mobility and defense sensing: DeepFusion AI
• Robotics and hardware: EFLOW and Riibotics
• Semiconductors: Ternell
• Education technology: Testbank

That spread is notable because it suggests a startup ecosystem that is not reliant on one narrow trend. The companies are building for different industries, but they share a need for scale, and in many cases for international customers.

What happens next?

The next step is the selection process for Startup Battlefield 200 and then, for the winning company and other finalists, the path toward Disrupt 2027. TechCrunch did not say which of the nine startups will ultimately make the final Battlefield 200 list, so that remains one open question. The Seoul pitch was only the first hurdle.

For Voinosis, the immediate questions are commercial as well as competitive. Can it close its Series A? Can it turn the reported clinical performance into repeatable sales with hospitals, senior living facilities, insurers or consumers? And can it maintain its claims around cross-language testing as it moves toward larger markets?

The same logic applies to the rest of the cohort. Investors and potential partners will be watching whether these startups can translate polished demos into real deployments, especially in the U.S. market they are targeting. That market is large, but it is also crowded and unforgiving.

What to watch

1. Which of the nine startups make it into Startup Battlefield 200.
2. Whether Voinosis secures a Series A and at what terms.
3. How the companies position themselves for U.S. customers after the Seoul event.
4. Whether products like Ternell’s memory architecture and Otition Medical’s imaging tools advance from technical claims to broader adoption.

The bigger picture

DETO 2026 offered a compact look at where South Korean deep tech is heading: more global, more specialized and more willing to meet investors on internationally recognized stages. TechCrunch’s report suggests that the U.S. is not an afterthought for these companies. It is the market they are building toward.

Voinosis may have won the pitch event, but the deeper story is the ecosystem around it. From healthcare diagnostics to chip memory and industrial robotics, these startups are chasing the same goal through very different technologies: prove the product, win trust and scale beyond home.